Wahlin Björn Engelbrekt, Ljungqvist Maria, Falk Ola, Rådman Therese, Lindé Sandra, Sonnevi Kristina
Division of Hematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Medical Unit Hematology, Karolinska University Hospital, Solna, Cancer, Stockholm, Sweden.
Ann Hematol. 2025 Jul 31. doi: 10.1007/s00277-025-06521-9.
Rituximab is a monoclonal antibody used in the treatment of B-cell malignancies. Infusion reactions are common during the first exposure but decrease with subsequent infusions. We here present our experience with a protocol for a 30-minute intravenous infusion of rituximab (SpeedR) to patients who have previously tolerated a 90-minute rituximab infusion. All patients were premedicated with 10 mg cetirizine and 1 g paracetamol (steroids were only given when part of a concomitant chemotherapy regimen). In this cohort 268 patients received a total of 940 intravenous 30-minute infusions with only nine patients having adverse reactions (all grade 1-2) which required little or no treatment. Out of the nine patients with reactions, seven were planned for more rituximab treatment and all of them could later continue with 30-minute rituximab infusions. We conclude that 30-minute rituximab infusions are a safe and efficient way to optimize workflow in the outpatient clinic and to give cost-effective treatment to lymphoma patients.
利妥昔单抗是一种用于治疗B细胞恶性肿瘤的单克隆抗体。首次输注时输注反应很常见，但后续输注时会减少。我们在此介绍我们对先前耐受90分钟利妥昔单抗输注的患者采用30分钟静脉输注利妥昔单抗（速溶型）方案的经验。所有患者均预先服用10毫克西替利嗪和1克对乙酰氨基酚（仅在同时进行化疗方案时给予类固醇）。在该队列中，268例患者共接受了940次30分钟的静脉输注，只有9例患者出现不良反应（均为1 - 2级），几乎不需要或无需治疗。在9例有反应的患者中，7例计划接受更多利妥昔单抗治疗，且所有患者后来都能够继续接受30分钟的利妥昔单抗输注。我们得出结论，30分钟的利妥昔单抗输注是优化门诊工作流程并为淋巴瘤患者提供经济有效治疗的一种安全且有效的方法。
